Effectiveness of 225Ac-labeled anti-EGFR radio immunoconjugate in EGFR positive KRAS and BRAF mutant colorectal cancer models

被引：0
|
作者：
Tikum, Anjong [1 ]
Babeker, Hanan [2 ]
Ketchemen, Jessica Pougoue [2 ]
Fonge, Humphrey [2 ]
Njotu, Fabrice Ngoh [2 ]
Nambisan, Anand [2 ]
Doroudi, Alireza [2 ]
机构：
[1] Univ Saskatchewan Bookstore, Saskatoon, SK, Canada
[2] Univ Saskatchewan, Saskatoon, SK, Canada
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P222
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway
    Russo, Antonio
    Rizzo, Sergio
    Bronte, Giuseppe
    Silvestris, Nicola
    Colucci, Giuseppe
    Gebbia, Nicola
    Bazan, Viviana
    Fulfaro, Fabio
    ONCOLOGY, 2009, 77 : 57 - 68
  • [42] The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
    Moradi-marjaneh, Reyhaneh
    Asgharzadeh, Fereshteh
    Khordad, Elnaz
    Marjaneh, Mahdi Moradi
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (07) : 942 - 952
  • [43] Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
    Tougeron, David
    Lecomte, Thierry
    Pages, Jean-Christophe
    Collin, Christine
    Villalva, Claire
    Ferru, Aurelie
    Tourani, Jean Marc
    Silvain, Christine
    Levillain, Pierre
    Karayan-Tapon, Lucie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
    Kyle Knickelbein
    Jingshan Tong
    Dongshi Chen
    Yi-Jun Wang
    Sandra Misale
    Alberto Bardelli
    Jian Yu
    Lin Zhang
    Oncogene, 2018, 37 : 4599 - 4610
  • [45] Beyond KRAS:Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
    Alfonso De Stefano
    Chiara Carlomagno
    World Journal of Gastroenterology, 2014, (29) : 9732 - 9743
  • [46] OUTCOME OF ANTI-EGFR ANTIBODY THERAPY IN METASTATIC COLORECTAL CANCER WITH LOW-FREQUENCY KRAS MUTATIONS
    Hikosaka, T.
    Yamazaki, K.
    Tsushima, T.
    Todaka, A.
    Yokota, T.
    Machida, N.
    Fukutomi, A.
    Onozawa, Y.
    Nakajima, T.
    Yasui, H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [47] Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
    De Stefano, Alfonso
    Carlomagno, Chiara
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (29) : 9732 - 9743
  • [48] Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
    Tougeron, D.
    Lecomte, T.
    Pages, J. C.
    Villalva, C.
    Collin, C.
    Ferru, A.
    Tourani, J. M.
    Silvain, C.
    Levillain, P.
    Karayan-Tapon, L.
    ANNALS OF ONCOLOGY, 2013, 24 (05) : 1267 - 1273
  • [49] Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
    Knickelbein, Kyle
    Tong, Jingshan
    Chen, Dongshi
    Wang, Yi-Jun
    Misale, Sandra
    Bardelli, Alberto
    Yu, Jian
    Zhang, Lin
    ONCOGENE, 2018, 37 (33) : 4599 - 4610
  • [50] New predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Masaki, Tadahiko
    Matsuoka, Hiroyoshi
    Kojima, Koichiro
    Asoh, Nobuyoshi
    Beniya, Ayumi
    Sakamoto, Yoshihiro
    Mori, Toshiyuki
    Abe, Nobutsugu
    CANCER SCIENCE, 2018, 109 : 1378 - 1378
12345